• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

IDCases . Doxycycline as a Potential Partner of COVID-19 Therapies

tetano

Editor, Senior Moderator
IDCases


. 2020 Jun 6;21:e00864.
doi: 10.1016/j.idcr.2020.e00864. eCollection 2020.
Doxycycline as a Potential Partner of COVID-19 Therapies


Alexandre E Malek[SUP] 1 [/SUP], Bruno P Granwehr[SUP] 1 [/SUP], Dimitrios P Kontoyiannis[SUP] 1 [/SUP]



Affiliations
Free PMC article

Abstract

Coronavirus disease 2019 (COVID-19) is a major public health challenge, and the current antiviral arsenal for treatment is limited, with questionable efficacy. Major efforts are under way for discovery of new effective agents, but the validation of new potential treatments for COVID-19 may take a long time. Therefore, the repurposing of existing drugs for new indications is needed. In this article, we argue for the potential benefits of using doxycycline with either hydroxycholoroquine or other putative agents for COVID-19 treatment, as doxycycline has antiviral and anti-inflammatory activities by dampening the cytokine storm and to prevent lung damage.

Keywords: 2019 novel coronavirus; COVID-19; Doxycycline; Hydroxychloroquine; Remdesivir.
 
Back
Top Bottom